JP2025508024A5 - - Google Patents
Info
- Publication number
- JP2025508024A5 JP2025508024A5 JP2024553180A JP2024553180A JP2025508024A5 JP 2025508024 A5 JP2025508024 A5 JP 2025508024A5 JP 2024553180 A JP2024553180 A JP 2024553180A JP 2024553180 A JP2024553180 A JP 2024553180A JP 2025508024 A5 JP2025508024 A5 JP 2025508024A5
- Authority
- JP
- Japan
- Prior art keywords
- section
- seq
- amino acid
- acid sequence
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317200P | 2022-03-07 | 2022-03-07 | |
| US63/317,200 | 2022-03-07 | ||
| US202263347748P | 2022-06-01 | 2022-06-01 | |
| US63/347,748 | 2022-06-01 | ||
| US202263374815P | 2022-09-07 | 2022-09-07 | |
| US63/374,815 | 2022-09-07 | ||
| PCT/IB2023/052086 WO2023170549A1 (en) | 2022-03-07 | 2023-03-06 | Treatment methods using ctla-4 and pd-1 bispecific antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508024A JP2025508024A (ja) | 2025-03-21 |
| JP2025508024A5 true JP2025508024A5 (https=) | 2026-03-13 |
Family
ID=87936206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553180A Pending JP2025508024A (ja) | 2022-03-07 | 2023-03-06 | Ｃｔｌａ－４及びｐｄ－１二重特異性抗体を使用した治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230322928A1 (https=) |
| EP (1) | EP4489781A4 (https=) |
| JP (1) | JP2025508024A (https=) |
| KR (1) | KR20240153603A (https=) |
| AU (1) | AU2023231766A1 (https=) |
| CA (1) | CA3253514A1 (https=) |
| IL (1) | IL315307A (https=) |
| TW (1) | TW202400656A (https=) |
| WO (1) | WO2023170549A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015176033A1 (en) * | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| IL260021B (en) * | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| JP7599205B2 (ja) * | 2018-06-01 | 2024-12-13 | アンヘレス セラピューティクス インコーポレイテッド | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
| WO2021023117A1 (zh) * | 2019-08-02 | 2021-02-11 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
| WO2023015292A1 (en) * | 2021-08-06 | 2023-02-09 | Xencor, Inc. | Prostate cancer treatment or treatment of gynecologic or genitourinary malignancy with a bispecific antibody that binds ctla4 and pd1 |
| TW202348788A (zh) * | 2022-04-01 | 2023-12-16 | 美商藝康美國公司 | 協同防汙劑組成物及使用其之方法 |
-
2023
- 2023-03-06 CA CA3253514A patent/CA3253514A1/en active Pending
- 2023-03-06 KR KR1020247032991A patent/KR20240153603A/ko active Pending
- 2023-03-06 JP JP2024553180A patent/JP2025508024A/ja active Pending
- 2023-03-06 US US18/178,687 patent/US20230322928A1/en active Pending
- 2023-03-06 IL IL315307A patent/IL315307A/en unknown
- 2023-03-06 EP EP23766218.4A patent/EP4489781A4/en active Pending
- 2023-03-06 AU AU2023231766A patent/AU2023231766A1/en active Pending
- 2023-03-06 WO PCT/IB2023/052086 patent/WO2023170549A1/en not_active Ceased
- 2023-03-07 TW TW112108310A patent/TW202400656A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023511595A5 (https=) | ||
| TW201545759A (zh) | 用於治療非小細胞肺癌之抗ｂ７－ｈ１及抗ｃｔｌａ－４抗體 | |
| JP2018538274A5 (https=) | ||
| JP2022512851A (ja) | がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン | |
| JP2024038034A (ja) | 膀胱癌の抗ｐｄ－ｌ１抗体治療 | |
| KR20180054492A (ko) | CD66c에 특이적으로 결합하는 항체 및 그의 용도 | |
| US20210388090A1 (en) | Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor | |
| JP2023545521A5 (https=) | ||
| TW202448943A (zh) | 含有抗ｃｅａｃａｍ５抗體－藥物接合物、抗ｖｅｇｆｒ－２抗體及抗ｐｄ１／ｐｄ－ｌ１抗體之抗腫瘤組合 | |
| US20240218066A1 (en) | Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancer | |
| JP2024536383A5 (https=) | ||
| KR20240038769A (ko) | 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법 | |
| JP2025508024A5 (https=) | ||
| KR20190107719A (ko) | 세리티닙 및 항-pd-1 항체 분자의 조합물에 대한 투여 일정 | |
| TW202500194A (zh) | 用於癌症治療中患者選擇之ＣＥＡＣＡＭ５ ｍＲＮＡ分析 | |
| US20190256603A1 (en) | Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer | |
| AU2022239502A1 (en) | Methods for treating cancer with anti-ilt3 antibodies | |
| JP2023512151A5 (https=) | ||
| JP7817242B2 (ja) | 鼻咽頭癌の治療における抗ｐｄ－１抗体の使用 | |
| WO2024213066A1 (en) | Combination therapies involving grem1 antagonists for treatment of cancer | |
| EP4694894A1 (en) | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor | |
| JP2026514105A (ja) | 癌の治療のためのｇｒｅｍ１拮抗薬が関与する併用療法 | |
| TW202515612A (zh) | 使用薩西土珠單抗戈維特坎及抗ｐｄ—１抗體或其抗原結合片段治療非小細胞肺癌 | |
| JP2025520098A (ja) | Ｎｓｃｌｃを処置するためのバイオマーカーおよび方法 | |
| EA045953B1 (ru) | Лечение рака мочевого пузыря с помощью антитела к pd-l1 |